Structural variation drives enhancer hijacking via 3D genome disruption in ccRCC - Summary - MDSpire

Structural variation drives enhancer hijacking via 3D genome disruption in ccRCC

  • By

  • Yu Dong

  • Wenjiao Xia

  • Zitong Yang

  • Liangliang Ren

  • Hongru Wang

  • Yiyang Zhou

  • Qinchen Li

  • Zhi Chen

  • Zhinan Xia

  • Yichun Zheng

  • Feifan Wang

  • Ning He

  • Bing Cheng

  • Dongmei Ma

  • Wei Shao

  • Wei Guo

  • Shuwen Wang

  • Ziqiao Liu

  • Junxiao Shen

  • Yiming Qi

  • Xuke Gong

  • Juan Jin

  • Bo Xie

  • Guixin Zhu

  • Cheng Zhang

  • January 6, 2026

  • 0 min

Share

Objective:

To investigate the role of structural variations (SVs) and 3D genome architecture in the pathogenesis of clear cell renal cell carcinoma (ccRCC).

Key Findings:
  • Identified novel variant targets in renal cancer linked to structural variation.
  • Revealed multidimensional 3D genome reorganization during ccRCC oncogenesis.
  • Validated a pathological enhancer hijacking event driving SEMA5B activation.
  • Developed a machine learning-based prognostic prediction model for ccRCC.
Interpretation:

The study highlights the significant interplay between structural variations and 3D genome architecture in ccRCC, suggesting that SVs can drive oncogenic regulation through alterations in chromatin organization.

Limitations:
  • The study primarily focuses on specific cell lines and may not fully represent the heterogeneity of ccRCC in patients.
  • Further validation in larger clinical cohorts is necessary to confirm the prognostic model's effectiveness.
Conclusion:

The findings enhance understanding of ccRCC's molecular basis and propose new therapeutic targets and biomarkers for precision oncology.

Original Source(s)

Structural variation drives enhancer hijacking via 3D genome disruption in ccRCC

  • by Yu Dong, Wenjiao Xia, Zitong Yang, Liangliang Ren, Hongru Wang, Yiyang Zhou, Qinchen Li, Zhi Chen, Zhinan Xia, Yichun Zheng, Feifan Wang, Ning He, Bing Cheng, Dongmei Ma, Wei Shao, Wei Guo, Shuwen Wang, Ziqiao Liu, Junxiao Shen, Yiming Qi, Xuke Gong, Juan Jin, Bo Xie, Guixin Zhu, Cheng Zhang

  • January 6, 2026

Related Content

This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark

REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR

  • May 25, 2026

  • 7 min
Sesquiterpenoids influence IFIT protein family and LIMK1: potential effects on the tumor microenvironment and macrophage infiltration

Evaluating the Prognostic Nutritional Index in Renal Cell Carcinoma Patients: A Comprehensive Systematic Review and Meta-Analysis Update